Anti-inflammatory activity of extracts of Bushen-Qiangdu-Zhilv decoction, a Chinese medicinal formula, in M1-polarized RAW264.7
© Huang et al.; licensee BioMed Central Ltd. 2014
Received: 22 May 2014
Accepted: 17 July 2014
Published: 28 July 2014
Bushen-Qiangdu-Zhilv Decoction (BQZ) is one of famous traditional Chinese medical formula for treating ankylosing spondylitis (AS). However, the mechanisms underlying effects of BQZ remains unknown. Pro-inflammatory cytokines, tumor necrosis factor (TNF)-α and interleukin (IL)-1, play an important role in AS. We therefore evaluated if BQZ could affect the expression of these cytokines.
Crude extracts were prepared and fractioned with petroleum ether (PE), ethyl acetate (EA), n-butanol (BU) and finally water (ACE). The stability of the extracts was confirmed by high-pressure liquid chromatography (HPLC) analysis. M1-polarized RAW264.7 was induced and subsequently treated with BQZ extracts. Quantitative real-time PCR experiments were performed to measure mRNA expression of TNF-α and IL-1.
It was found that TNF-α could be significantly suppressed by ACE extracts, whereas IL-1 was dramatically inhibited by BU extracts, which was further confirmed by dose-dependent experiments. Importantly, MTS assays showed that both ACE and BU extracts had a low cytotoxicity.
Altogether, our study indicates that BQZ decoction exerts anti-AS effects via its anti-inflammatory activity and may have a low side-effect. Further analysis of the extracts of BQZ decoction could lead to a discovery of some novel drugs adding to therapeutic strategy for AS patients.
Ankylosing spondylitis (AS) is a systemic inflammatory disease characterized by chronic inflammation of the axial skeleton, the peripheral joints, enthuses as well as the attachments of ligaments . The prevalence of AS is 0.20%–0.54% among Han-Chinese population, which is similar to the prevalence in Europe and America . Regarding therapeutic approaches aimed to treat AS, nonsteroidal anti-inflammatory drugs (NSAIDs) have been considered as the cornerstone of treatment for AS, but still, they are not effective in some cases. Disease-modifying antirheumatic drugs (DMARDs), such as sulfasalazine and methotrexate, are only recommended for treating AS with peripheral arthritis or extra-articular features [3, 4]. However, in cases of exclusive spinal involvement that do not respond to NSAIDs, the merely option is to adopt anti-tumor necrosis factor (TNF) agents . Because anti-TNF therapy suppresses the immune system , serious infections are the most frequently reported adverse events of interest across indications for the anti-TNF drugs . In addition, given the role of TNF in mediating tumor growth , the risk of malignancy with anti-TNF therapy has been a concern , and there is substantial evidence that the chronic inflammation inherent in the conditions treated with anti-TNF therapy is itself associated with an increased potential for malignancy [6, 8].
Fortunately, traditional Chinese medicine provides an alternative, or better, choice for AS patients. For example, traditional Chinese medical treatment, while effective in treating rheumatoid arthritis, appears to be less effective than Western medical treatment in controlling symptoms, but traditional Chinese medical treatment is associated with fewer side effects . Bushen-Qiangdu-Zhilv Decoction (BQZ) was established by Prof. Shu-De Jiao who is a well-known traditional Chinese medicine master in Rheumatology. Modified BQZ decoction has been demonstrated to be more effective than sulfasalazine, a typical DMARD for treating AS, in relieving clinical symptoms and signs as well as inflammatory activity indicators of AS patients . However, the mechanisms underlying BQZ decoction effects remains unclear. Herein, in this study, the crude extracts of BQZ decoction was prepared and fractioned, and effects of crude extracts of BQZ decoction on pro-inflammatory cytokines, TNF-α and interleukin (IL)-1, were determined.
Cell lines and cell culture
RAW 264.7 macrophage-like cell line was ordered from American Type Culture Collection (Rockville, MD, USA) and cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (FBS). To induce M1-polarized RAW264.7, 100 ng/ml interferon (IFN)-γ was added to cultures for 24 h prior to stimulation with crude extracts of BQZ decoction. Cell lines were propagated at 37°C in an atmosphere of 5% CO2.
Extraction and separation
The components of BQZ formula
Components of formula
Radix Rehmanniae Praeparata
Radix angelicae pubescentis
Medicinal cyathula root
Radix aconiti carmichaeli (Cooked and sliced)
honey-fried herba ephedrae
Rhizoma atractylodis macrocephalae
Raw semen coicis
Root of common peony
Radix paeoniae alba
Total 352 g of BQZ formula was boiled with 1.5 L ultrapure water in a Chinese medicine decocting pot (Guangzhou WEN XIN electronics co., LTD., China) for 2 h, yielding final 400 ml of solution. The obtained solution was filtered and subsequently dried using a centrifugal evaporator (Genevac Ltd., UK) for 48 h, following evaporated in a rotavapor (IKA laboratory, Germany) at 25°C. Finally, 6.4 g crude extract of BQZ decoction was obtained.
6.4 g of the crude extract were suspended in 400 ml ultrapure water and the solution was extracted three times with 500 ml of solvents of different polarity starting with petroleum ether (PE), ethyl acetate (EA), n-butanol (BU) and finally water (ACE). The obtained fractions were evaporated to dryness yielding 0.09 g petroleum ether, 0.72 g ethyl acetate, 0.549 g n-butanol and 4.50 g water fraction. High-pressure liquid chromatography (HPLC) analysis was performed as previously described . To observe which fractioned extracts is responsible for the BQZ effects, 50 μg/ml of these crude extracts were used to stimulate M1-polarized RAW264.7 for 24 h.
Flow cytometric analysis
The M1 polarized RAW264.7 was washed with PBS, and cells were subsequently stained with FITC-conjugated antibody, directed against cell surface marker CD86 , or with corresponding isotype controls for 20 min at 4°C. Cells were analyzed using FACSCalibur (Becton Dickinson, Erembodegem, Belgium). Data were analyzed using fluorescence-activated cell sorting (FACS) analysis and shown as mean fluorescent intensity (MFI).
Reverse transcriptase and quantitative real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, Grand Island, NY), and cDNA was subsequently synthesized from 2 μg of total RNA using a high capacity cDNA reverse transcription kit (Promega, Madison, WI), according to the manufacturer’s instruction. Quantitative real-time PCR was performed using gene-specific primers and SYBR Green qPCR SuperMix (Bio-Rad Laboratories, Inc. Berkeley, CA). The following primer sequences were used: GAPDH, (forward) 5′-GTTTTCAGGGATGAAGCGGC-3′and (reverse) 5′-TTTGTCAAGCTCATTTCCTGGTATG-3′; TNF-ɑ, (forward) 5′-GTGTCCCAACATTCATATTGTCAGT-3′and (reverse) 5′-TGGGAAGAGAAACCAGGGAGA-3′; IL-1, (forward) 5′-TGGGATAGGGCCTCTCTTGC-3′and (reverse) 5′-CCATGGAATCCGTGTCTTCCT-3′; arg1, (forward) 5′-TACAAGACAGGGCTCCTTTCAG-3′and (reverse) 5′-TGAGTTCCGAAGCAAGCCAA-3′; iNOS, (forward) 5′-TGAGTTCCGAAGCAAGCCAA-3′and (reverse) 5′-AGACCTCAACAGAGCCCTCA-3′.
Real-time PCR was performed using the CFX96 Touch Deep Well™ Real-Time PCR Detection System (Bio-Rad) with the following steps: 50°C 2 min, 95°C 10 min, 40 cycles at 95°C 15 s and 60°C 60 s. The expression of target genes in the treatment and control groups was normalized using the house-keeping gene GAPDH and the fold change in the expression of each target gene was calculated by the 2-ΔΔCT method.
Cytotoxicity of ACE and BU extracts was detected by MTS, i.e., CellTiter 96® AQueous One Solution Cell Proliferation Assay, according to the manufacturer’s instruction (Promega). Briefly, cells were seeded at the same density into 96-well plates and incubated overnight for attaching. After proper treatment, the control and treated cells were incubated for the indicated times. Following adding 20 μl of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] in each micro well, and plate was read using a microplate reader at wavelength of 492 nm (Bio-Rad, Philadelphia, PA, USA).
Data are shown as means ± SD from experiments repeated at least twice. For the comparisons between two groups, Student's t test was utilized. One-way ANOVA followed by Dunnett’s test was employed for comparisons among more than two groups. Statistical analyses were conducted by SPSS 11.6 statistical software (SPSS, Chicago, IL). A two-tailed P value of < 0.05 was considered to indicate statistical significance.
In vitro M1 macrophage polarization
Effects of crude extracts on TNF-α and IL-1 mRNA expression
ACE extracts suppressed TNF-α expression with a low cytotoxicity
To determine if the decreased levels of TNF-α mRNA were due to cell death, cells survival was examined by MTS assays. MTS assay is an update method from MTT assay, which is a typical and widely used tool for measurement of cell survival. After stimulation with 100 ng/ml IFN-γ, RAW264.7 was treated graded levels of ACE extracts for 24 h and MTS experiments were subsequently conducted. Surprisingly, ACE extracts did not affect cell survival significantly, even at the concentration of 500 μg/ml (Figure 4B). Our findings suggest that ACE extracts can suppress expression of TNF-α mRNA in M1-polarized RAW264.7 with a low cytotoxicity.
BU extracts suppressed IL-1 expression with a low cytotoxicity
Macrophage activation plays an important role in the pathology of AS [7, 10, 13]. Macrophages are a population of cells derived from CD34 positive bone marrow progenitors, from which blood pro-monocytes are differentiated and developed into monocytes which extravasate into tissues where they become “resident” tissue macrophages . Macrophages may be recruited and subsequently activated as consequence of any local disturbance of tissue homeostasis, such as infections, immune response and malignancy [7, 15]. Activated macrophages, also known as polarized macrophages, present different phenotypes, M1 (classical activation) and M2 (alternative activation) in general, in relation to the nature of the recruiting stimulus and the location [7, 16]. These two polarized phenotypes are considered to exhibit opposing activities, being either polarized towards pro-inflammatory or anti-inflammatory activity. Many pro-inflammatory cytokines, including TNF-α and IL-1, are derived from M1-polarized macrophages, and importantly these cytokines are associated with AS [17, 18]. Moreover, M1-polarized macrophages have been demonstrated to be expanded in AS patients . Mouse macrophage-like cell line RAW264.7 is, to some extent, an ideal macrophage model for in-vitro studies . Therefore, in this study, RAW264.7 was used as an in-vitro model, and M1 phenotype was polarized by exposure to IFN-γ .
Biological agents targeting inflammatory cytokines such as TNF-α have widely used in recent years as effective medications for treating AS, while numerous cases of the appearance of malignant tumors in patients receiving these drugs have been reported . In addition, not all AS patients achieve remission or a major clinical response to NSAIDs and TNF-α blockers . Though biological agents targeting IL-1, anakinra for example, has proven to be well tolerated and indicated in the treatment of rheumatoid arthritis, the data in AS are still lacking. Therefore, are there any alternatives?
BQZ decoction is a famous Chinese medicine formula with a long history for application in the treatment of AS. Crude extracts was prepared from BQZ decoction and subsequently fractioned. The effects of different fractioned extracts on the expression of pro-inflammatory cytokines were screened. Strikingly, in M1-polarized RAW264.7, ACE extracts could significantly suppress mRNA level of TNF-α, whereas BU extracts dramatically inhibited IL-1 mRNA expression. These findings suggest that BQZ decoction could be a natural antagonist to pro-inflammatory cytokines. To confirm this data, concentration-dependent experiments were conducted subsequently. The discovery of that TNF-α mRNA expression could be totally inhibited by ACE extracts suggests that BQZ decoction can be an alternative medication in AS patients intolerance to TNF-α blockers .
It is well-known that chronic inflammation in AS can lead to extensive new bone formation throughout the spine , and importantly, IL-1 may result in stimulation of bone formation [23, 24]. The data that expression of IL-1 mRNA was completely blocked by BU extracts implies that BQZ decoction is capable of relieving new bone formation. Therefore, BQZ decoction might be a better medication than many other biological agents targeting TNF-α, such as infliximab, etanercept, adalimumab, as the treatment of these agents does not halt new bone formation .
In addition, we tested if the decrease of TNF-α and IL-1 was due to the death of cells. Herein, MTS assays were conducted and the results turned out to be negative. Both ACE and BU extracts could not induce cell death in M1-polarized RAW264.7, suggesting the low cytotoxicity of the extracts of BQZ decoction. Considering modified BQZ decoction was more efficacious than sulfasalazine , the lower cytotoxicity of the extracts of BQZ decoction suggests that, compared with those Western medications, traditional Chinese medications could be a safer and better choice for treating AS.
In summary, with the low cytotoxicity, crude extracts of BQZ decoction fractioned with ACE and BU could block TNF-α and IL-1 mRNA expression in M1-polarized RAW264.7 respectively, suggesting that BQZ decoction could be an better and alternative medication for treating AS patients. Further analysis of fractioned extracts of BQZ decoction may lead to some novel drugs for treating AS with more efficacious and low toxicity.
This study was supported by National Natural Science Foundation of China (No. 81273736).
- Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Blanco R, Pina T, González-Juanatey C, Llorca J, González-Gay MA: Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. Biomed Res Int. 2014, 2014: 860651-PubMedPubMed CentralGoogle Scholar
- Zhai J, Rong J, Li Q, Gu J: Immunogenetic study in Chinese population with ankylosing spondylitis: are there specific genes recently disclosed?. Clin Dev Immunol. 2013, 2013: 419357-View ArticlePubMedPubMed CentralGoogle Scholar
- Slobodin G, Rosner I, Rimar D, Boulman N, Rozenbaum M, Odeh M: Ankylosing spondylitis: field in progress. Isr Med Assoc J. 2012, 14: 763-767.PubMedGoogle Scholar
- Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J, AIRE-MB group: Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence. 2013, 7: 961-972.View ArticlePubMedPubMed CentralGoogle Scholar
- Ciccia F, Alessandro R, Rizzo A, Accardo-Palumbo A, Raimondo S, Raiata F, Guggino G, Giardina A, De Leo G, Sireci G, Triolo G: Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis. Rheumatology (Oxford). 2014, 53: 104-113.View ArticleGoogle Scholar
- Baczynska D, Michalowska D, Witkiewicz W: The role of microRNA in ischemic diseases--impact on the regulation of inflammatory, apoptosis and angiogenesis processes. Przegl Lek. 2013, 70: 135-142. Article in PolishPubMedGoogle Scholar
- Maruotti N, Annese T, Cantatore FP, Ribatti D: Macrophages and angiogenesis in rheumatic diseases. Vasc Cell. 2013, 5: 11-View ArticlePubMedPubMed CentralGoogle Scholar
- Mizia-Malarz A, Sobol G, Wos H: Angiogenesis in the chronic inflammatory diseases and malignancies. Pol Merkur Lekarski. 2008, 24: 185-189. Article in PolishPubMedGoogle Scholar
- He YT, Ou AH, Yang XB, Chen W, Fu LY, Lu AP, Yan XP, Feng XH, Su L, Song YJ, Zeng SP, Liu W, Qian X, Zhu WH, Lao YR, Xu WH, Wen ZH, He XH, Wang BJ, Chen GX, Xue SQ: Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study. Rheumatol Int. 2014, 24: Epub ahead of printGoogle Scholar
- Szekanecz Z, Koch AE: Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol. 2007, 3: 635-643.View ArticlePubMedGoogle Scholar
- Li X, Zhang Y, Zeng X, Yang L, Deng Y: Chemical profiling of bioactive constituents in Sarcandra glabra and its preparations using ultra-high-pressure liquid chromatography coupled with LTQ Orbitrap mass spectrometry. Rapid Commun Mass Spectrom. 2011, 25: 2439-2447.View ArticlePubMedGoogle Scholar
- Davis MJ, Tsang TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, Olszewski MA: Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. mBio. 2013, 4: e00264-00213.View ArticlePubMedPubMed CentralGoogle Scholar
- Alvarez-Navarro C, de Lopez Castro JA: ERAP1 structure, function and pathogenetic role in ankylosing spondylitis and other MHC-associated diseases. Mol Immunol. 2014, 57: 12-21.View ArticlePubMedGoogle Scholar
- Singh A, Talekar M, Raikar A, Amiji M: Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. J Control Release. 2014, 14: 00239-9.Google Scholar
- Kharraz Y, Guerra J, Mann CJ, Serrano AL, Munoz-Canoves P: Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm. 2013, 2013: 491497-View ArticlePubMedPubMed CentralGoogle Scholar
- Locati M, Mantovani A, Sica A: Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol. 2012, 120: 163-184.View ArticleGoogle Scholar
- Monnet D, Kadi A, Izac B, Lebrun N, Letourneur F, Zinovieva E, Said-Nahal R, Chiocchia G, Breban M: Association between the IL-1 family gene cluster and spondyloarthritis. Ann Rheum Dis. 2012, 71: 885-890.View ArticlePubMedGoogle Scholar
- Lea WI, Lee YH: The associations between interleukin-1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis. Joint Bone Spine. 2012, 79: 370-374.View ArticlePubMedGoogle Scholar
- Hiroi M, Sakaeda Y, Yamaguchi H, Ohmori Y: Anti-inflammatory cytokine interleukin-4 inhibits inducible nitric oxide synthase gene expression in the mouse macrophage cell line RAW264.7 through the repression of octamer-dependent transcription. Mediators Inflamm. 2013, 2013: 369693-View ArticlePubMedPubMed CentralGoogle Scholar
- Sifuentes Giraldo W, Gonzalez Garcia A, Tojeiro SC, Sanchez-Sanchez O, Pian H, Diaz MV: Colonic perforation secondary to metastatic lung adenocarcinoma during anti-TNF treatment for ankylosing spondylitis. Acta Reumatol Port. 2014, 39: 72-76.PubMedGoogle Scholar
- Kiltz U, Heldmann F, Baraliakos X, Braun J: Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?. Curr Opin Rheumatol. 2012, 24: 252-260.View ArticlePubMedGoogle Scholar
- Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, King L, Poole AR, Inman RD: Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum. 2005, 52: 885-891.View ArticlePubMedGoogle Scholar
- Strand V, Kavanaugh AF: The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford). 2004, 43 (3): iii10-iii16.Google Scholar
- Watrous DA, Andrews BS: The metabolism and immunology of bone. Semin Arthritis Rheum. 1989, 19: 45-65.View ArticlePubMedGoogle Scholar
- Hreggvidsdottir HS, Noordenbos T, Baeten DL: Inflammatory pathways in spondyloarthritis. Mol Immunol. 2014, 57: 28-37.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/268/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.